Literature DB >> 20128612

Targeted dendrimeric anticancer prodrug: a methotrexate-folic acid-poly(amidoamine) conjugate and a novel, rapid, "one pot" synthetic approach.

Yuehua Zhang1, Thommey P Thomas, Ankur Desai, Hong Zong, Pascale R Leroueil, Istvan J Majoros, James R Baker.   

Abstract

A targeted dendrimeric anticancer prodrug, a conjugate of generation 5 (G5) polyamidoamine (PAMAM) dendrimer, folic acid (FA), and methotrexate (MTX), has been successfully synthesized by using a novel "one pot" approach which is simple, reproducible, and feasible for large-scale synthesis. All dendrimer products have been characterized by (1)H NMR, MALDI-TOF, GPC, and HPLC. With this new method, the ratio of FA versus MTX attached to the dendrimer can be easily tuned to achieve the desired therapeutic effect. A new analytical approach for calculating the numbers of FA and MTX attached to the dendrimer has been established. In vitro studies performed on FA receptor-expressing KB cells show that the new conjugate has a similar affinity and cytotoxic potency to G5-FA-MTX synthesized using the traditional multiple-step approach.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20128612      PMCID： PMC2892195          DOI： 10.1021/bc9003958

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN： 1043-1802            Impact factor:   4.774


  30 in total

1.  The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform.

Authors:  Seungpyo Hong; Pascale R Leroueil; István J Majoros; Bradford G Orr; James R Baker; Mark M Banaszak Holl
Journal:  Chem Biol       Date:  2007-01

2.  Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.

Authors:  Gianfranco Pasut; Fabiana Canal; Lisa Dalla Via; Silvia Arpicco; Francesco M Veronese; Oddone Schiavon
Journal:  J Control Release       Date:  2008-02-15       Impact factor: 9.776

3.  Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications.

Authors:  R Esfand; D A. Tomalia
Journal:  Drug Discov Today       Date:  2001-04-01       Impact factor: 7.851

4.  Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer.

Authors:  Jolanta F Kukowska-Latallo; Kimberly A Candido; Zhengyi Cao; Shraddha S Nigavekar; Istvan J Majoros; Thommey P Thomas; Lajos P Balogh; Mohamed K Khan; James R Baker
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

5.  HPLC separation of different generations of poly(amidoamine) dendrimers modified with various terminal groups.

Authors:  Mohammad T Islam; Xiangyang Shi; Lajos Balogh; James R Baker
Journal:  Anal Chem       Date:  2005-04-01       Impact factor: 6.986

Review 6.  Targeted drug delivery via the folate receptor.

Authors:  J Sudimack; R J Lee
Journal:  Adv Drug Deliv Rev       Date:  2000-03-30       Impact factor: 15.470

7.  Targeting and inhibition of cell growth by an engineered dendritic nanodevice.

Authors:  Thommey P Thomas; Istvan J Majoros; Alina Kotlyar; Jolanta F Kukowska-Latallo; Anna Bielinska; Andrzej Myc; James R Baker
Journal:  J Med Chem       Date:  2005-06-02       Impact factor: 7.446

8.  Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.

Authors:  S Wang; R J Lee; G Cauchon; D G Gorenstein; P S Low
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

9.  PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality.

Authors:  István J Majoros; Andrzej Myc; Thommey Thomas; Chandan B Mehta; James R Baker
Journal:  Biomacromolecules       Date:  2006-02       Impact factor: 6.988

Review 10.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213
View more
  5 in total

1.  Polyvalent dendrimer-methotrexate as a folate receptor-targeted cancer therapeutic.

Authors:  Thommey P Thomas; Baohua Huang; Seok Ki Choi; Justin E Silpe; Alina Kotlyar; Ankur M Desai; Hong Zong; Jeremy Gam; Melvin Joice; James R Baker
Journal:  Mol Pharm       Date:  2012-08-07       Impact factor: 4.939

2.  Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis.

Authors:  Thommey P Thomas; Sascha N Goonewardena; Istvan J Majoros; Alina Kotlyar; Zhengyi Cao; Pascale R Leroueil; James R Baker
Journal:  Arthritis Rheum       Date:  2011-09

3.  Design and in vitro validation of multivalent dendrimer methotrexates as a folate-targeting anticancer therapeutic.

Authors:  Thommey P Thomas; Melvin Joice; Madhuresh Sumit; Justin E Silpe; Alina Kotlyar; Sophia Bharathi; Jolanta Kukowska-Latallo; James R Baker; Seok Ki Choi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

4.  Polyvalent saccharide-functionalized generation 3 poly(amidoamine) dendrimer-methotrexate conjugate as a potential anticancer agent.

Authors:  Yuehua Zhang; Thommey P Thomas; Kyung-Hoon Lee; Minghsin Li; Hong Zong; Ankur M Desai; Alina Kotlyar; Baohua Huang; Mark M Banaszak Holl; James R Baker
Journal:  Bioorg Med Chem       Date:  2011-03-12       Impact factor: 3.641

5.  Dendrimer-Coated Gold Nanoparticles for Efficient Folate-Targeted mRNA Delivery In Vitro.

Authors:  Londiwe Simphiwe Mbatha; Fiona Maiyo; Aliscia Daniels; Moganavelli Singh
Journal:  Pharmaceutics       Date:  2021-06-17       Impact factor: 6.321
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.